Want to see TRDA full AI Analyst Report?
TRDA Stock Chart & Stats
$5.85
$0.23(3.93%)
At close: 4:00 PM EDT
$5.85
$0.23(3.93%)
Day’s Range― - ―
52-Week Range$4.93 - $16.45
Previous CloseN/A
Volume18.80K
Average Volume (3M)378.31K
Market Cap
$226.32M
Enterprise Value$322.86
Total Cash (Recent Filing)$254.86M
Total Debt (Recent Filing)$49.75M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 12, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding38,820,618
10 Day Avg. Volume453,749
30 Day Avg. Volume378,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.75Price Target Upside220.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$19.37M
Bulls Say, Bears Say
Bulls Say
Platform And Diversified Clinical PipelineEntrada's EEV platform underpins multiple clinical-stage programs (DMD, DM1, inherited retinal diseases) and a Vertex-partnered program, giving the company several independent development paths. Multiple programs and an external partnership provide durable 'shots on goal' and external validation that reduce single-program binary risk over the next 2–6 months as data readouts occur.
Modest Leverage And Equity CushionA low debt-to-equity ratio and a substantial equity base provide financial flexibility for a clinical-stage biotech. This modest leverage lowers short-term solvency risk, helps absorb R&D spending variability, and preserves optionality to fund trials via non-debt routes, supporting program execution over the medium term.
Near-term Cash Runway To Fund 2026 CatalystsWith roughly $255M reported cash and runway into Q3 2027, Entrada has the financing runway to advance multiple 2026 clinical readouts and regulatory steps without immediate capital raises. That runway gives management time to generate value-inflecting data or secure partnerships, reducing near-term dilution risk if execution proceeds as planned.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly -$132M TTM is structurally material for a clinical-stage biotech. Continued high burn to fund trials will deplete cash reserves absent new revenue or financing, forcing equity raises or partnerships that can dilute existing holders and constrain strategic flexibility over the next several quarters.
Revenue Collapse And Earnings VolatilityA ~77% revenue decline and a swing to a ~$166M net loss indicate volatile operating performance and weak current operating leverage. Reliance on sporadic collaboration revenue creates unpredictable top-line trends, complicating multi-quarter planning and increasing the likelihood of near-term financing needs if clinical spending continues to outpace revenue.
No Commercial Products; Funding Dependence And Dilution RiskAs a pre-revenue clinical-stage company without approved products, Entrada depends on collaborations, milestone payments, and external financing. The approved expansion of equity compensation capacity increases a structural dilution vector; absent near-term commercial revenues, continued reliance on equity or partnership financing elevates long-term dilution and execution risk.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $226.32M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.05.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,820,618 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.75 (220.51% Upside)
$18.75 (220.51% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biotechnology company focused on developing therapies for diseases that require delivering biologic drugs into cells. The company’s core technology platform, referred to publicly as Endosomal Escape Vehicle (EEV), is designed to enable the intracellular delivery of therapeutic cargoes such as peptides and proteins. Entrada’s pipeline includes programs aimed at neuromuscular and other serious diseases, including a program for Duchenne muscular dystrophy (DMD).
TRDA Stock 12 Month Forecast
Average Price Target
$18.75
▲(220.51% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
35.99% Insiders
8.15% Mutual Funds
0.07% Other Institutional Investors
46.79% Public Companies and
Individual Investors